HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare concluded the year with substantial financial flexibility, boasting $1.04 billion in cash and $5.78 billion in available credit facilities, coupled with a dividend increase of 8.3% to $0.78 per share. The company's EBITDA is projected to grow at a robust rate of 7.6% at the midpoint, supported by steady same-store volume growth and improved EBITDA margins of 21.1%, which exceeded expectations due to effective management. Additionally, HCA's commitment to expanding its capital expenditures to $5.0 billion-$5.5 billion in 2026 highlights its strategy to invest in high acuity programs and enhance its outpatient and inpatient capacity, positioning the company for continued growth.

HCA Healthcare's stock outlook is negatively impacted by lower-than-expected same-store revenue per adjusted admission, which at +2.9% fell short of both internal and consensus estimates. The company anticipates a significant decline in utilization of care, projecting a 30% decrease among the uninsured population, coupled with a shift towards Emergency Room usage, which could further strain revenue. Additionally, for 2026, HCA expects a $250 million to $450 million decline in net benefits from Medicaid Supplemental Payment programs, further exacerbating its financial challenges.